{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T20:14:24Z","timestamp":1781900064269,"version":"3.54.5"},"reference-count":63,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Hypereosinophilic syndrome (HES) is a rare condition characterized by elevated eosinophil levels and related symptoms of eosinophil-mediated organ damage. We reviewed the effectiveness and safety of mepolizumab for the treatment of HES. A scoping review was conducted following the PRISMA Scoping Reviews Checklist to identify real-world evidence of mepolizumab use in HES. In total, 36 references were identified as relevant and selected for review. Overall, 105 patients previously treated with glucocorticoids received mepolizumab at different dosages (range: 100\u2013750 mg), routes of administration (subcutaneous\/intravenous), and schedules (every 2\u201312 weeks). Remission rates were 57.1\u201376.0%. Most studies reported a range of 71.4\u201399.1% reduction in mean blood eosinophil counts with mepolizumab treatment. In addition, a glucocorticoid-sparing effect was observed; 85.7% of patients discontinued glucocorticoids after 12 months of mepolizumab administration. Mepolizumab was considered safe and well-tolerated and severe adverse events were rare. Mepolizumab provided clinically significant benefits in patients with HES in a real-world setting.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1704077","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T05:10:51Z","timestamp":1763097051000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Mepolizumab for hypereosinophilic syndrome: effectiveness and safety from real-world evidence"],"prefix":"10.3389","volume":"16","author":[{"given":"Elvira","family":"Mora","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Laura","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelina","family":"Lemes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Velasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas Mar\u00eda","family":"Hern\u00e1ndez-Rivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.jaci.2012.02.019","article-title":"Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes","volume":"130","author":"Valent","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-015-8506-7","article-title":"Ogbogu P hypereosinophilic syndrome","volume":"50","author":"Curtis","year":"2016","journal-title":"Clin Rev Allergy Immunol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/j.jaci.2009.09.022","article-title":"Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy","volume":"124","author":"Ogbogu","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27287","article-title":"World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management","volume":"99","author":"Shomali","year":"2024","journal-title":"Am J Hematol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/all.15544","article-title":"Proposed refined diagnostic criteria and classification of eosinophil disorders and related syndromes","volume":"78","author":"Valent","year":"2023","journal-title":"Allergy"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26352","article-title":"World Health Organization-defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Shomali","year":"2022","journal-title":"Am J Hematol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1146\/annurev-pathmechdis-012419-032756","article-title":"Contributions of eosinophils to human health and disease","volume":"15","author":"Klion","year":"2020","journal-title":"Annu Rev Pathol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2021.100809","article-title":"Hypereosinophilic syndromes \u2013 an enigmatic group of disorders with an intriguing clinical spectrum and challenging treatment","volume":"49","author":"Helbig","year":"2021","journal-title":"Blood Rev"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01765","article-title":"Eosinophilia associated With CD3\u2013CD4+ T cells: characterization and outcome of a single-center cohort of 26 patients","volume":"11","author":"Carpentier","year":"2020","journal-title":"Front Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2017.08.001","article-title":"Biologic agents for the treatment of hypereosinophilic syndromes","volume":"5","author":"Kuang","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1182\/HEMATOLOGY.2022000367","article-title":"Approach to the patient with suspected hypereosinophilic syndrome","author":"Klion","year":"2022","journal-title":"Hematology"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/AJH.25945","article-title":"Epidemiology, clinical picture and long-term outcomes of FIP1L1-PDGFRA-positive myeloid neoplasm with eosinophilia: Data from 151 patients","volume":"95","author":"Rohmer","year":"2020","journal-title":"Am J Hematol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/BJH.14488","article-title":"Guideline for the investigation and management of eosinophilia","volume":"176","author":"Butt","year":"2017","journal-title":"Br J Haematol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s13023-023-02696-4","article-title":"French guidelines for the etiological workup of eosinophilia and the management of hypereosinophilic syndromes","volume":"18","author":"Groh","year":"2023","journal-title":"Orphanet J Rare Dis"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2018.1.326","article-title":"Hypereosinophilic syndrome: approach to treatment in the era of precision medicine","author":"Klion","year":"2018","journal-title":"Hematology"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/9095275","article-title":"Eosinophils from physiology to disease: a comprehensive review","author":"Ramirez","year":"2018","journal-title":"BioMed Res Int"},{"key":"B17","volume-title":"Highlights of prescribing information. Nucala (mepolizumab)","year":"2015"},{"key":"B18","unstructured":"Summary of product characeteristics - Nucala\n          \n          \n          \n          2020"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.7326\/m18-0850","article-title":"PRISMA Extension for Scoping Reviews (PRISMA-ScR): checklist and explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann Intern Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1080\/1364557032000119616","article-title":"Scoping studies: towards a methodological framework","volume":"8","author":"Arksey","year":"2005","journal-title":"Int J Soc Res Methodol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1016\/j.jaip.2018.04.033","article-title":"Long-term clinical outcomes of high-dose mepolizumab treatment for hypereosinophilic syndrome","volume":"6","author":"Kuang","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"AB168","DOI":"10.1016\/j.jaci.2015.12.683","article-title":"Long term outcomes of mepolizumab treatment compared to conventional therapy for subjects with HES","volume":"137","author":"Kuang","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"AB110","DOI":"10.1016\/j.jaci.2022.12.351","article-title":"Low dose mepolizumab as steroid sparing strategy in HES remission phase","volume":"151","author":"Maule","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.jaci.2012.07.055","article-title":"RM Long term patient-adjusted maintenance schedule of mepolizumab is safe and effective in hypereosinophilic syndrome (HES)","volume":"95","author":"Paolini","year":"2010","journal-title":"Haematologica"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.annder.2021.12.002","article-title":"Skin manifestations of hypereosinophilic syndrome are polymorphous and difficult to treat: A retrospective cohort study","volume":"149","author":"Salomon","year":"2022","journal-title":"Ann Dermatol Venereologie"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2018.04.001","article-title":"Mepolizumab use: post-approval academic practice experience","volume":"121","author":"Benjamin","year":"2018","journal-title":"Ann Allerg Asthma Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa031261","article-title":"Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis","volume":"349","author":"Plotz","year":"2003","journal-title":"New Eng J Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-9343(03)00475-3","article-title":"Reversal of hypereosinophilic syndrome and lymphomatoid papulosis with mepolizumab and imatinib","volume":"115","author":"Koury","year":"2003","journal-title":"Am J Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2009.01.069","article-title":"Treatment of FIP1L1\/PDGFRA-negative hypereosinophilic syndrome with alemtuzumab, an anti-CD52 antibody","volume":"123","author":"Wagner","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2009.01.058","article-title":"Treatment of a case of pediatric hypereosinophilic syndrome with anti-interleukin-5","volume":"155","author":"Mehr","year":"2009","journal-title":"J Pediat"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2010.493132","article-title":"Current strategies in the management of hypereosinophilic syndrome, including mepolizumab","volume":"26","author":"Schwartz","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"B32","article-title":"Hypereosinophilic syndrome associated with regulatory T-cell disruption as a complication of stem cell transplantation","volume":"22","author":"Kersey-Barrett","year":"2012","journal-title":"J Investig Allergol Clin Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23120","article-title":"Treatment-refractory idiopathic hypereosinophilic syndrome: pitfalls and progress with use of novel drugs","volume":"87","author":"Bleeker","year":"2012","journal-title":"Am J Hematol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.oooo.2013.03.017","article-title":"Hypereosinophilic syndrome - lymphocytic variant transforming into peripheral T-cell lymphoma with severe oral manifestations","volume":"116","author":"D\u2019Elb\u00e9e","year":"2013","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2014.976823","article-title":"Lymphocytic variant hypereosinophilic syndrome progressing to angioimmunoblastic T-cell lymphoma","volume":"56","author":"Roufosse","year":"2015","journal-title":"Leuk Lymph"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-11-551614","article-title":"How I treat hypereosinophilic syndromes","volume":"126","author":"Klion","year":"2015","journal-title":"Blood"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1089\/mab.2016.0038","article-title":"Tolerance and efficacy with simultaneous use of two monoclonal antibodies for a patient with hypereosinophilic syndrome and ulcerative colitis","volume":"35","author":"Patel","year":"2016","journal-title":"Monoclon Antib Immunodiagn Immunother"},{"key":"B38","doi-asserted-by":"publisher","first-page":"bcr","DOI":"10.1136\/bcr-2016-218992","article-title":"Therapeutic effect of anti-IL-5 on eosinophilic myocarditis with large pericardial effusion","author":"Song","year":"2017","journal-title":"BMJ Case Rep"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2018.02.032","article-title":"Hypereosinophilic syndrome presenting acutely with neurologic signs","volume":"120","author":"Brunet","year":"2018","journal-title":"Ann Allerg Asthma Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01198","article-title":"Efficacy and safety of mepolizumab (anti-interleukin-5) treatment in Gleich\u2019s syndrome","volume":"9","author":"Matucci","year":"2018","journal-title":"Front Immunol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/pai.12809","article-title":"Mepolizumab-a novel option for the treatment of hypereosinophilic syndrome in childhood","volume":"29","author":"Schwarz","year":"2018","journal-title":"Pediatr Allergy Immunol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.bcmd.2017.04.008","article-title":"Resolution of a steroid-resistant, hypereosinophilic immune diathesis with mepolizumab and concomitant amelioration of a mixed thrombotic microangiopathy","volume":"69","author":"Mulvey","year":"2018","journal-title":"Blood Cells Mol Dis"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1016\/j.jaip.2018.06.017","article-title":"A case of chronic eosinophilic pneumonia successfully treated with mepolizumab","volume":"6","author":"To","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2020.01.028","article-title":"Hypereosinophilia with angioimmunoblastic T-cell lymphoma","volume":"124","author":"Eng","year":"2020","journal-title":"Ann Allerg Asthma Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201907-1376IM","article-title":"The effect of mepolizumab on the lungs in a boy with hypereosinophilic syndrome","volume":"202","author":"Domany","year":"2020","journal-title":"Am J Respir Crit Med"},{"key":"B46","doi-asserted-by":"publisher","first-page":"39","DOI":"10.23822\/EurAnnACI.1764-1489.112","article-title":"Familial clustering of hypereosinophilic diseases treated with mepolizumab: a case report from Japan","volume":"52","author":"Kurosawa","year":"2020","journal-title":"Eur Ann Allergy Clin Immunol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/PDE.14594","article-title":"Anti-IL-5 (mepolizumab) therapy for Wells syndrome associated idiopathic hypereosinophilic syndrome in young children","volume":"38","author":"Weiss","year":"2021","journal-title":"Ped Dermatol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1111\/aor.13895","article-title":"A case of hypereosinophilic syndrome with Loeffler endocarditis successfully bridged to heart transplantation by biventricular mechanical support","volume":"45","author":"Di Nora","year":"2021","journal-title":"Artif Organs"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.102871","article-title":"Hypereosinophilic syndrome with central nervous system involvement treated with anti-IL-5 therapy","volume":"51","author":"Jonakowski","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2022.08.809","article-title":"Treatment of hypereosinophilia with mepolizumab in a 6-year-old boy","volume":"129","author":"Eubanks","year":"2022","journal-title":"Ann Allerg Asthma Immunol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2022.04.031","article-title":"Treatment of a 4-year-old boy with mepolizumab for lymphocytic hypereosinophilic syndrome","volume":"129","author":"Cascio","year":"2022","journal-title":"Ann Allerg Asthma Immunol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.18502\/ijaai.v21i2.9229","article-title":"Korean adolescent patient with manifestations of lymphocyte variant hypereosinophilic syndrome and episodic angioedema with eosinophilia, treated with reslizumab","volume":"21","author":"Jue","year":"2022","journal-title":"Iran J Allergy Asthma Immunol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/J.JACI.2020.08.037","article-title":"Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial","volume":"146","author":"Roufosse","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"4431","DOI":"10.1016\/j.jaip.2021.07.050","article-title":"Safety and efficacy of mepolizumab in hypereosinophilic syndrome: an open-label extension study","volume":"9","author":"Gleich","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/ART.41943","article-title":"Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis (EGPA): a European multicenter observational study","volume":"74","author":"Bettiol","year":"2021","journal-title":"Arth Rheumatol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2024.2417184","article-title":"Long-term safety of mepolizumab for up to \u223c10 years in patients with severe asthma: open-label extension study","volume":"56","author":"Pavord","year":"2024","journal-title":"Ann Med"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA070812\/SUPPL_FILE\/NEJMOA070812-SA1.PDF","article-title":"Treatment of patients with the hypereosinophilic syndrome with mepolizumab","volume":"358","author":"Rothenberg","year":"2008","journal-title":"New Eng J Med"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2012.07.055","article-title":"Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes","volume":"131","author":"Roufosse","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/j.jaip.2020.08.039","article-title":"Clinical development of mepolizumab for the treatment of severe eosinophilic asthma: on the path to personalized medicine","volume":"9","author":"Pavord","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1111\/ALL.15056","article-title":"From DREAM to REALITI-A and beyond: mepolizumab for the treatment of eosinophil-driven diseases","volume":"77","author":"Pavord","year":"2022","journal-title":"Allergy"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-023-02918-9","article-title":"Low-dose anti-IL 5 treatment in idiopathic hypereosinophilic syndrome: towards a precision medicine approach for remission maintenance","volume":"18","author":"Caminati","year":"2023","journal-title":"Orphanet J Rare Dis"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1600728","article-title":"Clinical and immunological biomarkers in hypereosinophilic syndrome: the second step after diagnostic algorithms","volume":"12","author":"Longhino","year":"2025","journal-title":"Front Med"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2023.03.011","article-title":"Unmet needs and evidence gaps in hypereosinophilic syndrome and eosinophilic granulomatosis with polyangiitis","volume":"151","author":"Wechsler","year":"2023","journal-title":"J Allergy Clin Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1704077\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T05:10:53Z","timestamp":1763097053000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1704077\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,14]]},"references-count":63,"alternative-id":["10.3389\/fimmu.2025.1704077"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1704077","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,14]]},"article-number":"1704077"}}